Zymeworks Inc. (ZYME) News
Follow Zymeworks Inc. (ZYME) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 30 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Zymeworks Is Maintained at Buy by Citigroup
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 06:09 PM UTC
H
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks Inc. (NASDAQ: ZYME ) on Monday finalized its acquisition of Theravance Biopharma, releasing final transaction details and updated financial guidance for fiscal year 2026. The biotechnology company projects 2026
LIVE | Sep 28, 2026, 05:06 PM UTC
H
Weekly Recap: Zymeworks Inc. raises 2026 guidance and secures $350M lien
Zymeworks Inc. (NASDAQ:ZYME) lifted 2026 guidance after acquiring Theravance and FDA approval of Ziihera, targeting $278—$292M revenue and $114—$128M adjusted EBITDA while securing $350M senior notes with a first—priorit
EARNINGS | Sep 28, 2026, 11:05 AM UTC
H
Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M
Zymeworks Inc. (NASDAQ: ZYME ), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final transact
LIVE | Sep 28, 2026, 10:12 AM UTC
L
Zymeworks Inc Expects Total Revenue, Including Collaboration Revenue From Yupelri, For 2026 To Be Between $278 Million And $292 Million
Zymeworks Inc NASDAQ:ZYME
NEWS | Sep 28, 2026, 10:05 AM UTC
L
Zymeworks Sees 2026 Adj EBITDA of $114M-$128M >ZYME
Zymeworks Sees 2026 Adj EBITDA of $114M-$128M >ZYME
NEWS | Sep 28, 2026, 10:02 AM UTC
L
Zymeworks Inc. (ZYME) Closes Theravance Deal, Guides 2026 Revenue $278M—$292M
Zymeworks closed its Theravance Biopharma acquisition, adding YUPELRI cash flows, and guided 2026 revenue to $278M—$292M and Adjusted EBITDA to $114M—$128M.Material DetailsContext by AI AnalystThis is a mid-cycle shift t
MNA | Sep 28, 2026, 10:02 AM UTC
L
Zymeworks Sees 2026 Rev $278M-$292M >ZYME
Zymeworks Sees 2026 Rev $278M-$292M >ZYME
NEWS | Sep 28, 2026, 10:01 AM UTC
H
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. NASDAQ:ZYME, a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifu
MNA | Sep 28, 2026, 10:01 AM UTC
H
Zymeworks Raises $350 Million Notes and Launches Ampreloxetine CVR
Zymeworks announced multiple material agreements tied to its merger closing, including a $350 million senior secured note financing and a Contingent Value Rights (CVR) Agreement linked to ampreloxetine. The notes, purcha
CENTRAL_BANK | Sep 23, 2026, 08:15 PM UTC
L
Zymeworks Inc. (ZYME) Closes Acquisition of Theravance Biopharma
Zymeworks completed the previously announced acquisition of Theravance Biopharma. The company will host a call at 8:30 am ET on Sept. 28 to discuss final transaction details.Material DetailsContext by AI AnalystThis is a
MNA | Sep 23, 2026, 08:02 PM UTC
L
Zymeworks Completes Acquisition of Theravance Biopharma
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. NASDAQ:ZYME, a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifu
MNA | Sep 23, 2026, 08:02 PM UTC
L
ZYME - Zymeworks Completes Acquisition of Theravance Biopharma
ZYME - Zymeworks Completes Acquisition of Theravance Biopharma
MNA | Sep 23, 2026, 08:01 PM UTC
L
ZYME: FDA approval, robust pipeline, and strategic partnerships drive growth and shareholder value
FDA approval of zanidatamab in HER2-positive gastric cancer establishes a new standard of care and drives significant royalty and milestone potential. The pipeline is advancing with multiple phase III readouts and innova
REGULATION | Sep 14, 2026, 10:56 PM UTC
L
ZYME: FDA approval and a robust pipeline drive growth through innovation and royalty streams
FDA approval of zanidatamab in HER2-positive gastric cancer marks a new standard of care, with significant royalty and milestone potential. The pipeline includes next-gen T-cell engagers, ADCs, and innovative multispecif
REGULATION | Sep 14, 2026, 10:48 PM UTC
L
ZYME: FDA approval, pipeline progress, and strategic buybacks drive a hybrid royalty and R&D model
FDA approval of zanidatamab and a robust pipeline position the company for significant royalty and milestone revenues, with additional late-stage assets and innovative R&D programs advancing. Strategic share buybacks, ac
REGULATION | Sep 14, 2026, 09:45 PM UTC
L
Theravance facing several lawsuits seeking to block Zymeworks acquisition
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
MNA | Sep 10, 2026, 03:11 PM UTC
M
ZYME shares strength on recent FDA approval and acquisitions
ZYME’s recent FDA approval for zanidatamab in GEA is cited as setting a new standard of care and boosting sales projections, alongside growth plans tied to royalties, strategic acquisitions, and R&D.
MNA | Sep 08, 2026, 09:19 PM UTC
L
ZYME cites FDA approval and acquisitions to drive growth
ZYME says a recent FDA approval and commercial launch of zanidatamab in GEA supported growth. It also highlights a strategy combining royalty aggregation, R&D innovation, and acquisitions including Theravance.
REGULATION | Sep 08, 2026, 08:52 PM UTC
L
JP Morgan maintains Zymeworks at Overweight
JP Morgan maintained its Overweight rating on Zymeworks.
EQUITY | Sep 03, 2026, 09:21 PM UTC
L
SJM, ZYME Stocks Hit 52-Week High — What’s Driving The Surge Today?
SJM, ZYME Stocks Hit 52-Week High — What’s Driving The Surge Today?
EQUITY | Aug 26, 2026, 05:59 PM UTC
L
Zymeworks Is Maintained at Buy by Citigroup
Zymeworks Is Maintained at Buy by Citigroup
EQUITY | Aug 26, 2026, 03:49 PM UTC
L
Citizens maintains $32.00/share price target on Zymeworks
TradingView News reports Citizens maintained a $32.00/share price target for Zymeworks shares.
EQUITY | Aug 26, 2026, 12:56 PM UTC
M
FDA Approves Ziihera (zanidatamab-hrii) for first-line HER2+ GE adenocarcinoma
U.S. FDA approves Ziihera (zanidatamab-hrii) with and without Tislelizumab plus chemotherapy in first-line HER2+ advanced gastroesophageal adenocarcinoma.
EQUITY | Aug 25, 2026, 02:23 PM UTC
H
US FDA Sets August PDUFA Dates
FDA sets PDUFA dates for several biotech companies
REGULATION | Jul 30, 2026, 03:53 PM UTC
H
Zymeworks price target raised to $31 from $28 at Truist
Truist raised the firm's price target on Zymeworks to $31 from $28 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The firm is ant
EARNINGS | Jul 07, 2026, 01:15 PM UTC
L
Zymeworks shares are trading higher after Wells Fargo raised its price target on the stock from $34 to $37.
Zymeworks shares are trading higher after Wells Fargo raised its price target on the stock from $34 to $37.
EQUITY | Jun 30, 2026, 04:47 PM UTC
L
Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $37
Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ: ZYME ) with a Overweight and raises the price target from $34 to $37.
EQUITY | Jun 30, 2026, 02:24 PM UTC
M
Theravance Biopharma Discloses Termination Fee Of $32.5M After Acquisition Offer By Zymeworks
The Merger Agreement contains certain customary termination rights for the Company and Parent. Subject to the terms and conditions of the Merger Agreement, the Company or Parent may terminate the Merger Agreement if the
MNA | Jun 29, 2026, 10:43 AM UTC
H
Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M
Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition of Theravance Biopharma at
EARNINGS | Jun 29, 2026, 10:04 AM UTC